Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Fucosyltransferase 4 promotes cancer metastasis via enhancing EGFR/TGFBR signaling network and is associated with poor prognosis in non-small cell lung cancer

ABSTRACT: Fucosyltransferase 4 promotes cancer metastasis via enhancing EGFR/TGFBR signaling network and is associated with poor prognosis in non-small cell lung cancer

PROVIDER: PRJNA493790 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Fucosyltransferase 4 promotes cancer metastasis via enhancing EGFR/TGFBR signaling network and is associated with poor prognosis in non-small cell lung cancer

Project description:Purpose: Aberrant glycosylation has been known to regulate cancer cell trafficking via promoting intravascular adhesion during metastasis. Clinicopathological studies have also shown a strong correlation between aberrant glycosylation and invasive/metastatic potentials of human cancers. However, the major glycosylation enzymes that drive lung cancer metastases and the signaling networks involved in the process remain incompletely understood. Methods: Two lung adenocarcinoma cell lines, A549 and CL1-0 cells, with FUT4 overexpression and 81 lung cancer tissues and 19 adjacent lung tissues underwent RNA extraction for RNA-seq analysis. Results: We identified fucosyltransferase 4 (FUT4) as a strong predictor of patient prognosis from this RNA-seq cohort. Conclusions: High levels of FUT4 in tumor tissues significantly correlate with poor prognosis in NSCLC patients.

2020-07-15 | GSE120622 | GEO

MYC regulation of a "poor prognosis" metastatic cancer cell state

Project description:MYC regulation of a "poor prognosis" metastatic cancer cell state

| PRJNA111899 | ENA

Reduced phosphorylated ATM expression is associated with poor prognosis and gemcitabine resistance in pancreatic cancer

Project description:Background & Aims: Loss of ataxia-telangiectasia mutated, occurring in patients with multiple primary malignancies, including pancreatic cancer, is associated with poor prognosis. This study investigated the detailed molecular mechanism through which ataxia-telangiectasia mutated expression affects the prognosis of pancreatic-cancer patients Methods: Ataxia-telangiectasia mutated and phosphorylated ataxia-telangiectasia mutated levels in pancreatic-cancer patients who underwent surgical resection were analyzed using immunohistochemistry staining. RNA sequencing was performed on ataxia-telangiectasia mutated-knockdown pancreatic-cancer cells to elucidate the mechanism underlying the involvement of ataxia-telangiectasia mutated in pancreatic cancer. Results: Immunohistochemical analysis showed that 15.3% and 27.8% of clinical samples had low levels of ataxia-telangiectasia mutated and phosphorylated ataxia-telangiectasia mutated, respectively. Low phosphorylated ataxia-telangiectasia mutated expression substantially reduced overall and disease-free survival in pancreatic-cancer patients. Loss of ataxia-telangiectasia mutated promoted MET and NTN1 over-expression via hypoxia-inducible factor-1α, thereby enhancing pancreatic-cancer cell proliferation and migration. Conclusions: These results demonstrate that the loss of ataxia-telangiectasia mutated activates downstream proto-oncogenes, inhibits apoptosis, and promotes tumor growth; moreover, loss of phosphorylated ataxia-telangiectasia mutated leads to poor prognosis in pancreatic-cancer patients. Thus, ataxia-telangiectasia mutated may serve as a potential molecular marker to monitor patient prognosis and as a potential target for pancreatic cancer therapy

2023-02-13 | GSE224882 | GEO

Distinct gene expression profile between ARID1Ahigh and good prognosis and ARID1Alow and poor prognosis groups

Project description:Cancer tissue specimens from ARID1Ahigh and good prognosis and ARID1Alow and poor prognosis of patients with advanced gastric cancer were extracted and analyzed.

2018-02-06 | GSE110078 | GEO

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Project description:Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

| PRJNA499054 | ENA

Circulating PMN-MDSCs correlates with poor prognosis in metastatic hormone sensitive prostate cancer

Project description:Circulating PMN-MDSCs correlates with poor prognosis in metastatic hormone sensitive prostate cancer

| PRJNA853305 | ENA

Methylation of Cancer Stem Cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients

Project description:Methylation of Cancer Stem Cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients

| PRJNA149357 | ENA

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer

Project description:Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype and the lack of specific signature makes difficult the development of targeted therapeutic strategy. We previously found that PRICKLE1, an evolutionary conserved protein acting as a regulator of vertebrate development, is upregulated in TNBC. Proteomic approaches allowed us to decipher the protein complex associated to PRICKLE1 in TNBC. Within that complex, we identified a large subset of proteins involved in the regulation of Rho-GTPase family members. We build a metagene with regulators of small G-protein activity and we found that this metagene is overexpressed in TNBC and is a poor prognosis marker. We analyzed the combination of the metagene expression and PRICKLE1 expression and identified that combined expression of ECT2 and PRICKLE1 provides a worst prognosis than PRICKLE1 expression alone in TNBC. ECT2 is a GEF for Rac1 and we showed that PRICKLE1 regulate the enzymatic activity of ECT2. Finally, we also observed that Ect2 and Prickle1 are functionally connected during evolution since both act synergistically to coordinate cellular movement during vertebrate gastrulation. Our results demonstrate the pivotal role of PRICKLE1 in TNBC and build the path for development of targeted therapeutic strategies to heal TNBC patients.

2019-10-15 | PXD011253 | Pride

MicroRNA expression contributes to the poor prognosis of human small cell lung cancer

Project description:MicroRNAs are important cellular components and their dysfunctions are associated with various disease.Small-cell lung cancer (SCLC) is an aggressive disease with a poor prognosis, but little is know about the underlying machinery that leads to rapid tumor growth and early metastases.In this study, clinical outcome prediction miRNAs were successfully found through expression profiling of a total of 924 miRNA genes in 42 SCLC cases.

2011-02-22 | GSE27435 | GEO

Mitochondrial aconitase (ACO2) modulates iron homeostasis and is associated with outcomes in poor prognosis aggressive non-small cell lung cancer

Project description:NSCLC accounts for 85% of lung cancers, the most frequently diagnosed and leading cause of cancer related death. An ACO2-iron acis regulates intracellular iron and consequently the particularly aggressive phenotype associated with NSCLC engraftment and poor prognosis. These findings suggest that NSCLC stratified by ACO2 protein level may benefit from treatments that target iron homeostasis.

2022-09-19 | PXD028556 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data